Key takeaways from the updated multidisciplinary European MASLD guidelines
The new European clinical practice guidelines from three scientific societies (European Association for the Study of the Liver, European Association for the Study of Diabetes and European Association for the Study of Obesity) on the management of metabolic dysfunction-associated steatotic liver dise...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-06-01
|
| Series: | eGastroenterology |
| Online Access: | https://egastroenterology.bmj.com/content/3/2/e100196.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849708015118188544 |
|---|---|
| author | Frank Tacke Paul Horn |
| author_facet | Frank Tacke Paul Horn |
| author_sort | Frank Tacke |
| collection | DOAJ |
| description | The new European clinical practice guidelines from three scientific societies (European Association for the Study of the Liver, European Association for the Study of Diabetes and European Association for the Study of Obesity) on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) provide detailed recommendations on diagnosis, risk stratification, monitoring strategies, treatment and prevention. Lifestyle interventions (eg, weight reduction, Mediterranean diet, exercise, alcohol abstinence) and the treatment of cardiometabolic risk factors continue to be the mainstay of treatment and prevention of the disease. Incretin mimetics that are approved to treat obesity and/or type 2 diabetes such as semaglutide and tirzepatide have benefits for ameliorating metabolic dysfunction-associated steatohepatitis (MASH). Novel developments include adapted strategies for screening (case finding) using non-invasive tests (NITs) with a focus on detecting fibrosis or cirrhosis, risk-adjusted monitoring of MASLD by NITs as well as the recommendation to use, if locally approved, the thyroid hormone receptor β-agonist resmetirom in patients with non-cirrhotic MASH fibrosis (≥F2 stage). |
| format | Article |
| id | doaj-art-9aeeaeca84d44bc9a34aafe343aaf54d |
| institution | DOAJ |
| issn | 2766-0125 2976-7296 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | eGastroenterology |
| spelling | doaj-art-9aeeaeca84d44bc9a34aafe343aaf54d2025-08-20T03:15:47ZengBMJ Publishing GroupeGastroenterology2766-01252976-72962025-06-013210.1136/egastro-2025-100196Key takeaways from the updated multidisciplinary European MASLD guidelinesFrank Tacke0Paul Horn11 Department of Hepatology and Gastroenterology, Charité—Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany1 Department of Hepatology and Gastroenterology, Charité—Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, GermanyThe new European clinical practice guidelines from three scientific societies (European Association for the Study of the Liver, European Association for the Study of Diabetes and European Association for the Study of Obesity) on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) provide detailed recommendations on diagnosis, risk stratification, monitoring strategies, treatment and prevention. Lifestyle interventions (eg, weight reduction, Mediterranean diet, exercise, alcohol abstinence) and the treatment of cardiometabolic risk factors continue to be the mainstay of treatment and prevention of the disease. Incretin mimetics that are approved to treat obesity and/or type 2 diabetes such as semaglutide and tirzepatide have benefits for ameliorating metabolic dysfunction-associated steatohepatitis (MASH). Novel developments include adapted strategies for screening (case finding) using non-invasive tests (NITs) with a focus on detecting fibrosis or cirrhosis, risk-adjusted monitoring of MASLD by NITs as well as the recommendation to use, if locally approved, the thyroid hormone receptor β-agonist resmetirom in patients with non-cirrhotic MASH fibrosis (≥F2 stage).https://egastroenterology.bmj.com/content/3/2/e100196.full |
| spellingShingle | Frank Tacke Paul Horn Key takeaways from the updated multidisciplinary European MASLD guidelines eGastroenterology |
| title | Key takeaways from the updated multidisciplinary European MASLD guidelines |
| title_full | Key takeaways from the updated multidisciplinary European MASLD guidelines |
| title_fullStr | Key takeaways from the updated multidisciplinary European MASLD guidelines |
| title_full_unstemmed | Key takeaways from the updated multidisciplinary European MASLD guidelines |
| title_short | Key takeaways from the updated multidisciplinary European MASLD guidelines |
| title_sort | key takeaways from the updated multidisciplinary european masld guidelines |
| url | https://egastroenterology.bmj.com/content/3/2/e100196.full |
| work_keys_str_mv | AT franktacke keytakeawaysfromtheupdatedmultidisciplinaryeuropeanmasldguidelines AT paulhorn keytakeawaysfromtheupdatedmultidisciplinaryeuropeanmasldguidelines |